{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:44:44Z","timestamp":1774442684383,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T00:00:00Z","timestamp":1412553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Impax Laboratories"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.parkreldis.2014.08.004","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T13:33:30Z","timestamp":1408109610000},"page":"1335-1340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Comparison of IPX066 with carbidopa\u2013levodopa plus entacapone in advanced PD patients"],"prefix":"10.1016","volume":"20","author":[{"given":"Fabrizio","family":"Stocchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Dillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherron","family":"Kell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneel","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2014.08.004_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib2","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.parkreldis.2014.08.004_bib3","first-page":"IV37","article-title":"Does levodopa slow or hasten the rate of progression of Parkinson's disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ana.23890","article-title":"Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?","volume":"73","author":"deSouza","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","article-title":"Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients","volume":"44","author":"Nutt","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2125.2002.01654.x","article-title":"Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa\/carbidopa dose","volume":"54","author":"Heikkinen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib10","first-page":"S42","article-title":"Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials","volume":"55","author":"Kieburtz","year":"2000","journal-title":"Neurology"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.parkreldis.2014.08.004_bib11","first-page":"S2","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib12","series-title":"Stalevo\u00ae (carbidopa levodopa and entacapone) tablets prescribing information","year":"2011"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/mds.22587","article-title":"Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies","volume":"24","author":"LeWitt","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib14","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/mds.23861","article-title":"Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/ern.11.195","article-title":"IPX066: a novel carbidopa-levodopa extended-release formulation","volume":"12","author":"Hauser","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A\u00a0home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life. The EuroQol Group","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","article-title":"Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial","volume":"12","author":"Hauser","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib22","series-title":"Relative bioavailability of IPX066 to carbidopa-levodopa formulations","year":"2011"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib23","series-title":"Comtan\u00ae full prescribing information","year":"2011"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib24","series-title":"A\u00a0Study to compare IPX066 and carbidopa\/levodopa\/entacapone (CLE) followed by an open-label safety study of IPX066 in advanced Parkinson's disease","year":"2011"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib25","first-page":"235","article-title":"International (NL-UK) double-blind study of sinemet CR and standard sinemet (25\/100) in 170 patients with fluctuating Parkinson's disease","volume":"243","author":"Wolters","year":"1996","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","author":"Parkinson Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.08.004_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410390504","article-title":"The response to levodopa in Parkinson's disease: imposing pharmacological law and order","volume":"39","author":"Nutt","year":"1996","journal-title":"Ann Neurol"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014003022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014003022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:06Z","timestamp":1761178446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802014003022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1353802014003022"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.08.004","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of IPX066 with carbidopa\u2013levodopa plus entacapone in advanced PD patients","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}